No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CYTO Altamira Therapeutics
- 1.4300
- -0.0500-3.38%
Close May 22 16:00 ET
3.20MMarket Cap-166P/E (TTM)
1.5200High1.4300Low37.24KVolume1.4500Open1.4800Pre Close55.52KTurnover1.68%Turnover RatioLossP/E (Static)2.24MShares17.600052wk High0.45P/B3.17MFloat Cap1.350052wk Low--Dividend TTM2.22MShs Float636800.0000Historical High--Div YieldTTM6.08%Amplitude1.3500Historical Low1.4900Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Altamira Therapeutics Announces Filing Of Provisional Patent Application For OligoPhore Nanoparticles With SiRNA Targeting P65 Protein In Treatment Of Cancer And Inflammation
Express News | Altamira Therapeutics Announces Filing of Provisional Patent Application for Oligophore Nanoparticles With Sirna Targeting P65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Announces Publication of Positive Results From Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Investor Conference on April 18, 2024. The
Altamira Therapeutics Announces 2024 Annual Meeting
Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Altamira Therapeutics Ltd.
Comments
$Altamira Therapeutics(CYTO.US$
NEWS
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
NEWS
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
$Altamira Therapeutics(CYTO.US$ Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
3 MINUTES AGO, 8:47 AM EDT
VIA GLOBENEWSWIRE
3 MINUTES AGO, 8:47 AM EDT
VIA GLOBENEWSWIRE
1
Revolutionary Collaboration: Altamira Therapeutics and Univercells Group Join Forces on Nanoparticle-Delivered mRNA Vaccines.
In an era where medical innovation is more critical than ever, a groundbreaking collaboration between Altamira Therapeutics Ltd. and Univercells Group has emerged, signaling a potential leap forward in the way vaccines are delivered. Announced on March 25, 2024, this partnership aims to ha...
In an era where medical innovation is more critical than ever, a groundbreaking collaboration between Altamira Therapeutics Ltd. and Univercells Group has emerged, signaling a potential leap forward in the way vaccines are delivered. Announced on March 25, 2024, this partnership aims to ha...
2
$Altamira Therapeutics(CYTO.US$ 60 million naked shorts. 🖕🖕🖕 Crooked Ken Griffin
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg